Company Overview

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, it offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. The company was founded in 1992 and is based in Cincinnati, Ohio.

  • Name

    Medpace Holdings, Inc.

  • CEO

    Dr. August James Troendle M.D.

  • Website

    www.medpace.com

  • Sector

    Life Sciences Tools and Services

  • Year Founded

    1992

Profile

  • Market Cap

    $11.18B

  • EV

    $10.82B

  • Shares Out

    30.93M

  • Revenue

    $2,030.05M

  • Employees

    5,800

Margins

  • Gross

    66.91%

  • EBITDA

    20.17%

  • Operating

    18.79%

  • Pre-Tax

    19.56%

  • Net

    16.74%

  • FCF

    24.77%

Returns (5Yr Avg)

  • ROA

    14.43%

  • ROTA

    37.93%

  • ROE

    34.99%

  • ROCE

    31.59%

  • ROIC

    14.55%

Valuation (TTM)

  • P/E

  • P/B

  • EV/Sales

  • EV/EBITDA

  • P/FCF

  • EV/Gross Profit

Valuation (NTM)

  • Price Target

    $406.91

  • P/E

  • PEG

  • EV/Sales

  • EV/EBITDA

  • P/FCF

Financial Health

  • Cash

    $510.89M

  • Net Debt

    -$357.17M

  • Debt/Equity

    0.2

  • EBIT/Interest

    690.22

Growth (CAGR)

  • Rev 3Yr

    25.45%

  • Rev 5Yr

    20.89%

  • Rev 10Yr

    22.68%

  • Dil EPS 3Yr

    31.9%

  • Dil EPS 5Yr

    35.18%

  • Dil EPS 10Yr

    21.35%

  • Rev Fwd 2Yr

    13.24%

  • EBITDA Fwd 2Yr

    17.42%

  • EPS Fwd 2Yr

    21.18%

  • EPS LT Growth Est

    16.52%

Dividends

  • Yield

  • Payout

  • DPS

  • DPS Growth 3Yr

  • DPS Growth 5Yr

  • DPS Growth 10Yr

  • DPS Growth Fwd 2Yr

NasdaqGS:MEDP